DNB Carnegie Access: EQL Pharma: Q3 2025/26 initial: Beat driven by strong branded sales
DNB Carnegie has published a new flash comment on EQL Pharma following recent news flow.
To access the full report and subscribe to future updates, https://access.dnbcarnegie.com/companies/1387